The purpose of SMA Europe is to provide a framework to stimulate collaboration and accelerate translational research pathways in SMA and promote patient care.

  1. Welcoming 3 countries to SMA Europe

    We are delighted to have welcomed three new organisations into our fold: MDA Hellas (Greece) MDA Hellas is a muscular disease association founded in 2000, which focuses on improving the lives of individuals with neuromuscular disorders: not only on forging a lasting working relationship with government agencies and on enlisting the help of private institutions […]


  2. Nicole Gusset appointed President of SMA Europe with immediate effect

    SMA Europe is delighted to announce that Nicole Gusset has been appointed as President. This appointment is effective immediately and follows Mencía de Lemus’ decision to step down as president of SMA Europe. We are fortunate to have someone of Nicole Gusset’s calibre step up to lead SMA Europe.  Nicole has a scientific background, working […]


  3. Update on the clinical development of risdiplam

    Following our request to receive important and timely information about the risdiplam clinical development programme, Roche has shared with us an update on part 1 of the FIREFISH clinical trial. FIREFISH is an open-label, two-part pivotal clinical trial in infants with Type 1 SMA. Part 1 was a dose-escalation study in 21 infants with the […]